Related Experiment Video
Updated: Aug 2, 2026
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
Published on: September 16, 2012
[German multicenter thalassemia study. Concept and initial results]
E Kohne1, K Stahnke, A E Kulozik
1Universitäts-Kinderklinik Ulm.
Insights
This study on Thalassaemia major in Germany found that many young patients need improved transfusion therapy and iron chelation. Optimizing treatment protocols is crucial for better long-term outcomes and quality of life.
Area of Science:
- Pediatric Hematology
- Genetic Blood Disorders
Background:
- Over 300 children and adolescents in Germany have Thalassaemia major.
- Current treatment protocols may be suboptimal, necessitating standardized therapeutic approaches.
Purpose of the Study:
- To implement and evaluate a standardized therapy protocol for Thalassaemia major patients.
- To assess the effectiveness and side effects of the protocol in a multi-center study.
- To identify areas for improving patient care and long-term prognosis.
Main Methods:
- A multi-center study initiated in April 1991 involving children and adolescents with Thalassaemia major.
- Therapy protocol includes regular erythrocyte transfusions to maintain hemoglobin above 10.5 g/dl.
- Daily subcutaneous Desferal administration (40 mg/kg) for iron elimination.
Main Results:
- Preliminary data from 74 patients indicate that most can benefit from improved therapy.
- 40.9% of patients exhibited suboptimal transfusion therapy with HbF levels above 15%.
- At least 30% of patients require intensified iron elimination therapy.
Conclusions:
- Preliminary findings highlight the urgent need to enhance Thalassaemia major treatment in Germany.
- The study aims to enroll all affected patients to optimize long-term quality of life and prognosis.
- Standardized protocols are essential for improving outcomes in pediatric patients with Thalassaemia major.
Abstract:
At present more than 300 children and adolescents with Thalassaemia major are living in the FRG. The purpose of this project is--for the first time--to apply a standardized therapy protocol to these patients, to prove its effectivity and study side-effects. The multi-center study started in April 1991. The therapy is based on periodical transfusion of erythrocytes in order to keep haemoglobin (Hb) concentration (= basic Hb-value) above 10.5 g/dl, and daily application of Desferal, 40 mg/kg bw s.c. for iron elimination. Until Nov. 30, 1991 74 patients from 31 different childrens hospitals entered the study. Preliminary results after evaluation of the basic questionnaires can be summarized as follows: 1. The majority of patients if not too old to highly profit from improvement of therapy; 2. In 40.9% of these patients HbF concentration was higher than 15%, which indicates a suboptimal transfusion therapy; 3. At least 30% of patients need intensified iron elimination. Even these preliminary data demonstrate the necessity to improve the therapy of Thalassaemia major in Germany. The goal is to include all affected patients in the study and so optimize long term results concerning quality of life and prognosis.
More Related Videos
11:59Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
06:50A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
Published on: May 29, 2020